Eli Lilly Reportable Segment — Marketing, selling, and administrative decreased by 6.3% to $2.93B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.9%, from $2.47B to $2.93B. Over 3 years (FY 2022 to FY 2025), Reportable Segment — Marketing, selling, and administrative shows an upward trend with a 19.9% CAGR.
An increase relative to revenue may signal aggressive investment in new product launches, while a decrease could indicate cost-optimization efforts or reduced commercial activity.
Captures the operating expenses related to the promotion, distribution, and general management of the segment's business...
Comparable to SG&A expenses allocated to specific business units in peer pharmaceutical companies.
lly_segment_reportable_segment_marketing_selling_and_administrative| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.61B | $1.61B | $1.61B | $1.61B | $1.85B | $1.85B | $1.85B | $1.85B | $1.95B | $2.12B | $2.10B | $2.42B | $2.47B | $2.75B | $2.74B | $3.13B | $2.93B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +15.0% | +0.0% | +0.0% | +0.0% | +5.5% | +8.5% | -0.8% | +15.5% | +1.8% | +11.5% | -0.4% | +14.3% | -6.3% |
| YoY Change | — | — | — | — | +15.0% | +15.0% | +15.0% | +15.0% | +5.5% | +14.4% | +13.4% | +31.0% | +26.4% | +30.0% | +30.5% | +29.1% | +18.9% |